Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Ranya Dajani joined Advaxis as Vice President, Corporate Development from Bristol-Myers Squibb Co. (BMS), where she worked for nearly 20 years in business development and finance.

“Ranya brings deep experience in leading strategic corporate positioning and executing dozens of transactions for one of the leading immuno-oncology companies,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “Her extensive corporate development expertise will prove invaluable as we develop multiple cancer immunotherapies with our proprietary Lm Technology™.”

Ms. Dajani held several finance and business development roles at BMS of increasing responsibility before serving as its executive director for investor relations. In her roles in business development, she was responsible for executing several important strategic collaborations, including key partnerships in immuno-oncology. She holds a master’s degree in business administration with a concentration in finance and a master’s of arts in economics, both from Boston University, and a bachelor’s in economics from the University of Michigan.

“With the unique capabilities of Lm Technology™, a robust pipeline of novel product candidates and track record of being a strong collaborator, Advaxis is well positioned to advance immuno-oncology therapies for a wide range of cancers,” said Ms. Dajani. “I am excited to join the team.” (Original Source)

Shares of Advaxis closed yesterday at $8.67, up $0.06 or 0.70%. ADXS has a 1-year high of $22.20 and a 1-year low of $5.21. The stock’s 50-day moving average is $8.53 and its 200-day moving average is $8.08.

On the ratings front, Advaxis has been the subject of a number of recent research reports. In a report issued on July 6, FBR analyst Vernon Bernardino reiterated a Buy rating on ADXS. Separately, on June 29, H.C. Wainwright’s Swayampakula Ramakanth reiterated a Buy rating on the stock and has a price target of $23.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Swayampakula Ramakanth have a total average return of -16.5% and -16.3% respectively. Bernardino has a success rate of 31% and is ranked #3932 out of 4038 analysts, while Ramakanth has a success rate of 28% and is ranked #3918.

The street is mostly Bullish on ADXS stock. Out of 4 analysts who cover the stock, 4 suggest a Buy rating . The 12-month average price target assigned to the stock is $21.00, which implies an upside of 142.2% from current levels.

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company’s platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.